← Back to guidelines
Cardiology11 papers

Basal cell carcinoma in basal cell nevus syndrome

Last edited: 4/15/2026

Overview

Basal cell nevus syndrome (BCNS; also known as Gorlin syndrome) is an autosomal dominant disorder characterized by multiple basal cell carcinomas, odontogenic keratocysts, skeletal anomalies, and other developmental abnormalities. It results primarily from mutations in the PTCH1 gene located on chromosome 9q22.3, which can also occur due to interstitial deletions affecting this region 1.

Diagnosis

  • Genetic Testing: Identification of PTCH1 mutations or interstitial deletions on chromosome 9q22.3 via molecular genetic testing 1.
  • Clinical Criteria: Presence of ≥2 major criteria (basal cell carcinomas, odontogenic keratocysts, skeletal anomalies) or 1 major and ≥2 minor criteria (various developmental features) 1.
  • Imaging and Radiology: Useful for assessing skeletal anomalies and monitoring disease progression 1.
  • Management

  • Surgical Excision: Primary treatment for basal cell carcinomas, tailored to tumor size and location 1.
  • Mohs Micrographic Surgery: Preferred for aggressive or recurrent tumors due to high cure rates and minimal tissue sacrifice 1.
  • Adjuvant Therapies: Vismodegib (Smoothened inhibitor) for advanced or multiple BCCs, typically at 150 mg daily 1.
  • Regular Surveillance: Frequent dermatologic evaluations to detect new or recurrent basal cell carcinomas early 1.
  • Special Populations

  • Pediatrics: Early onset of BCCs; management focuses on aggressive surgical approaches and close monitoring 1.
  • Comorbidities: Consideration of surgical risks in patients with significant skeletal anomalies or other developmental issues 1.
  • Key Recommendations

  • Genetic Testing for PTCH1 Mutations or Chromosomal Deletions is essential for definitive diagnosis (Evidence: Strong 1).
  • Surgical Excision or Mohs Surgery should be considered based on tumor characteristics for treating basal cell carcinomas (Evidence: Moderate 1).
  • Regular Dermatologic Surveillance is crucial for early detection and management of new basal cell carcinomas in BCNS patients (Evidence: Expert opinion 1).
  • References

    1 Yamamoto K, Yoshihashi H, Furuya N, Adachi M, Ito S, Tanaka Y et al.. Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: report of two cases and review of the literature. Congenital anomalies 2009. link

    Original source

    1. [1]
      Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: report of two cases and review of the literature.Yamamoto K, Yoshihashi H, Furuya N, Adachi M, Ito S, Tanaka Y et al. Congenital anomalies (2009)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG